Compare BMR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMR | CMMB |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | Israel | Israel |
| Employees | N/A | 12 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 20.5M |
| IPO Year | 2021 | 2023 |
| Metric | BMR | CMMB |
|---|---|---|
| Price | $1.26 | $2.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 28.1K | ★ 106.6K |
| Earning Date | 02-26-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $55.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $1.35 |
| 52 Week High | $3.24 | $3.55 |
| Indicator | BMR | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 40.40 |
| Support Level | $1.22 | $1.47 |
| Resistance Level | $1.41 | $2.21 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 47.37 | 8.97 |
Beamr Imaging Ltd provides content-adaptive video compression solutions for human viewing and machine vision. The company is trusted by technology companies such as NVIDIA and Amazon Web Services, and serves media companies including Netflix, Paramount, and JioHotstar. Using Emmy-winning patented technology, its solutions help deliver media content with high quality while reducing storage and delivery costs. Its customers include over-the-top content distributors, video streaming platforms, and Hollywood studios that use its products to store, distribute, and monetize video and images across devices. The company operates in the United States, Israel, and the rest of the world, with the United States generating maximum revenue.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.